Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
| Revenue (TTM) | $780.57M |
| Gross Profit (TTM) | $693.64M |
| EBITDA | $419.16M |
| Operating Margin | 30.00% |
| Return on Equity | 23.70% |
| Return on Assets | 7.27% |
| Revenue/Share (TTM) | $24.62 |
| Book Value | $9.51 |
| Price-to-Book | 3.68 |
| Price-to-Sales (TTM) | 1.44 |
| EV/Revenue | 1.972 |
| EV/EBITDA | 3.84 |
| Quarterly Earnings Growth (YoY) | 31.50% |
| Quarterly Revenue Growth (YoY) | 12.90% |
| Shares Outstanding | $32.41M |
| Float | $31.39M |
| % Insiders | 0.94% |
| % Institutions | 121.31% |
Volatility is currently contracting